U.S. FDA approves AbbVie's drug for Parkinson's disease
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
· 9/26/2026, 5:47:52 AM· 2 min read
The drug tavapadon, which AbbVie gained access to through its $8.7 billion acquisition of Cerevel Therapeutics in 2023, comes as a once-a-day pill
Read original story →Related stories
health
India orders crackdown on nicotine pouches, citing health risks, letter shows
health
WHO says Congo Ebola outbreak spreads to two new health zones
health
Focus should be on preventive health screening: Prathap C. Reddy
health